Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Imatinib AND Glivec

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    128 result(s) found for: Imatinib AND Glivec. Displaying page 3 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2005-003166-42 Sponsor Protocol Number: CSTI571BDE55 Start Date*: 2005-12-27
    Sponsor Name:University of Leipzig
    Full Title: Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer.
    Medical condition: Patients with histologically proven adenocarcinoma of the gallbladder/bile duct (not papillary cancer) in an advanced stage, who have not responded to a first line chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004585 Bile duct adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013295-48 Sponsor Protocol Number: 22505 Start Date*: 2009-09-04
    Sponsor Name:Århus University Hospital, Department of Dermatology
    Full Title: Treatment of patients with Nephrogenic Systemic Fibrosis(NSF) with Imatinib Mesylate(Glivec). An open label clinical trial among patients with moderate to severe NSF.
    Medical condition: Nephrogenic Systemic Fibrosis (NSF) is a fibrosing disease strongly associated with Gadolinium Based Contrast Agents(GBCA). Hard dermal plaques appear on legs, arms and abdomen. The lesions involve...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067467 Nephrogenic systemic fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-006181-41 Sponsor Protocol Number: CA180399 Start Date*: 2013-01-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy wi...
    Medical condition: Chronic Phase Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) BE (Completed) IT (Completed) AT (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-000898-39 Sponsor Protocol Number: SSGXXII Start Date*: 2014-12-19
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.
    Medical condition: gastrointestinal stromal tumor (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000218-19 Sponsor Protocol Number: CSTI571BDE59 Start Date*: 2008-05-21
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatmen...
    Medical condition: prostrate carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016922-15 Sponsor Protocol Number: HSJD-IMANF1 Start Date*: 2010-02-04
    Sponsor Name:HOSPITAL SANT JOAN DE DÉU
    Full Title: ENSAYO PILOTO CON IMATINIB PARA PACIENTES CON NEUROFIBROMA PLEXIFORME ASOCIADO A LA NEUROFIBROMATOSIS TIPO I. PILOT STUDY WITH IMATINIB FOR PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE I PATIENTS
    Medical condition: Tratamiento de los neurofibromas plexiformes de alto riesgo no abordables quirúrgicamente en pacientes con neurofibromatosis tipo I
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001805-34 Sponsor Protocol Number: CSTI571I1203 Start Date*: 2017-08-15
    Sponsor Name:Novartis Pharma K.K
    Full Title: Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
    Medical condition: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia (Ph+ALL)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-001339-69 Sponsor Protocol Number: CML-paed-II-Study Start Date*: 2008-01-25
    Sponsor Name:THE TECHNICAL UNIVERSITY OF DRESDEN
    Full Title: Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). A mult...
    Medical condition: Newly diagnosed patients with BCR-ABL-positive CML
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002538-20 Sponsor Protocol Number: EORTC 62027 Start Date*: 2006-02-24
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF rearrangement i.e. DermatoFib...
    Medical condition: Soft tissue sarcomas are a family of malignant diseases originating from mesenchymal cells. Two types of theses sarcomas, dermatofibrosarcoma protuberans (DFSP) and giant cell fibriblastoma(GCF), a...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057070 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003883-20 Sponsor Protocol Number: CSTI571JDE74 Start Date*: 2008-09-30
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection
    Medical condition: gastrointestinal stromal tumors - adjuvant treatment after surgical tumor resection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) SK (Completed) CZ (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-006457-27 Sponsor Protocol Number: CHUBX 2006/05 Start Date*: 2007-02-27
    Sponsor Name:CHU de Bordeaux
    Full Title: Essai clinique de phase II, comparatif, randomisé, en double insu, de l’imatinib mésylate STI571 (Glivec®) versus placebo chez des malades atteints de sclérodermie cutanée grave et de sclérodermie ...
    Medical condition: sclérodermie cutanée grave et de sclérodermie systémique avec atteinte cutanée grave
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-012616-40 Sponsor Protocol Number: CAMN107A2405 Start Date*: 2009-08-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by ...
    Medical condition: Chronic Myelogenous Leukemia in Chronic Phase
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005569-12 Sponsor Protocol Number: CSTI571E2203 Start Date*: 2006-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial...
    Medical condition: pulmonary arterial hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005102-42 Sponsor Protocol Number: INTERIM 0407 Start Date*: 2007-12-19
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: Phase II explorative study of intermittent Imatinib (IM) treatment (INTERIM) in elderly patients with Ph+ chronic myeloid leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) w...
    Medical condition: Patients with CML Ph+ CP that are in cytogentic response complete and stable for the last two years, treated with a Glivec daily dose
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009014 Chronic myeloid leukaemia (in remission) LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000657-29 Sponsor Protocol Number: CSTI571K2301 Start Date*: 2005-07-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP)...
    Medical condition: Newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    M15 10009013
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001547-43 Sponsor Protocol Number: ET19-075 Start Date*: 2022-01-18
    Sponsor Name:Centre Léon Bérard
    Full Title: ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectabl...
    Medical condition: Unresectable locally advanced or metastatic gastrointestinal stromal tumors (GIST) after failure of standard treatments
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000770-36 Sponsor Protocol Number: 2009-18 Start Date*: 2013-05-14
    Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
    Full Title:
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007094-20 Sponsor Protocol Number: IB 2009-07 Start Date*: 2009-07-17
    Sponsor Name:Institut Bergonié
    Full Title: Étude multicentrique de phase III évaluant L’efficacité d’une stratégie d’adaptation de dose de l’imatinib mésylate sur la réponse moléculaire chez des patients présentant une leucémie myéloïde chr...
    Medical condition: Patients présentant une leucémie myéloïde chronique en phase chronique (LMCPC) traités par IM depuis au moins 2 ans, en réponse cytogénétique complète depuis au moins 1 an, avec une maladie résidue...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009015 Chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005255-87 Sponsor Protocol Number: 2014-13 Start Date*: 2016-05-04
    Sponsor Name:Assistance Publique Hôpitaux de MARSEILLE
    Full Title: Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study.
    Medical condition: Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade Index
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007988-16 Sponsor Protocol Number: GICNO08.002 Start Date*: 2009-05-08
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Imatinib piu` idrossiurea nel trattamento dei meningiomi recidivati o in progressione: studio randomizzato di fase II.
    Medical condition: patients affected by recurrent or progressive meningiomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 02:29:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA